View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 1, 2020updated 12 Jul 2022 11:48am

Moderna starts dosing in Phase II Covid-19 vaccine trial

Moderna has started dosing the first participants in all age cohorts of the Phase II clinical trial of its Covid-19 vaccine candidate, mRNA-1273.

Moderna has started dosing the first participants in all age cohorts of the Phase II clinical trial of its Covid-19 vaccine candidate, mRNA-1273.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

mRNA-1273 is an mRNA vaccine encoding for a prefusion stabilised form of the Spike (S) protein, which was chosen by the company in alliance with Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID).

The Phase II trial will assess the safety, reactogenicity and immunogenicity of two vaccinations of mRNA-1273 administered 28 days apart. It is set to involve 600 healthy participants across the age groups of 18-55 and 55 and above.

Participants will receive either a 50μg dose, a 100μg dose, or placebo at both vaccinations and will be followed for 12 months after the second vaccination.

In the Phase I trial of the vaccine candidate, 25μg and 100μg dose levels demonstrated neutralising antibody titers at or above convalescent sera and were observed to be generally well-tolerated.

Moderna has decided to drop the assessment of the 250μg dose in the Phase II trial.

The US Food and Drug Administration (FDA) completed a review of the company’s investigational new drug (IND) application for the vaccine candidate on 6 May and granted fast track designation on 12 May.

Moderna reported initial results from the Phase I trial of mRNA-1273 led by the NIAID on 18 May, where the 25µg and 100µg dose levels showed dose dependent increases in immunogenicity, as well as between prime and boost.

The company intends to work with the NIAID to launch a Phase III trial in July. The dose for the Phase III study is expected to be between 25µg and 100µg.

Moderna noted that the planning for these studies was supported by funding from the Biomedical Advanced Research and Development Authority (BARDA).

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena